Autolus enters CAR-T race with FDA approval for Aucatzyl

Watch out, Gilead and Novartis: there's a new CAR-T in town.

Autolus is ready to hit the ground running after winning FDA approval for its Aucatzyl, a late entry to the heated CD19 CAR-T cell therapy arena.